UNLABELLED: With antiangiogenic agents, tumor shrinkage may be absent, despite survival benefit. The present study assessed the predictive value of molecular imaging for the identification of survival benefit during antiangiogenic treatment with bevacizumab and erlotinib in patients with advanced non-small cell lung cancer. METHODS: Patients were evaluated using an imaging protocol including CT, 18F-FDG PET, H2(15)O PET, and dynamic contrast-enhanced MRI to derive measurements on tumor size, glucose metabolism, perfusion, and microvascular permeability. The percentage change in imaging parameters after 3 wk of treatment as compared with baseline was calculated and correlated with progression-free survival (PFS). RESULTS: Forty-four patients were included, and 40 underwent CT and 18F-FDG PET at both time points. Complete datasets, containing all imaging modalities, were available for 14 patients. Bevacizumab and erlotinib treatment resulted in decreased metabolism, perfusion, and tumor size. A decrease in standardized uptake value or tumor perfusion of more than 20% at week 3 was associated with longer PFS (9.7 vs. 2.8 mo, P=0.01, and 12.5 vs. 2.9 mo, P=0.009, respectively). Whole-tumor Ktrans (the endothelial transfer constant) was not associated with PFS, but patients with an increase of more than 15% in the SD of tumor Ktrans values-that is, an increase in regions with low or high Ktrans values-after 3 wk had shorter PFS (2.3 vs. 7.0 mo, P=0.008). A partial response, according to the response evaluation criteria in solid tumors (RECIST), at week 3 was also associated with prolonged PFS (4.6 vs. 2.9 mo, P=0.017). However, 40% of patients with a partial response as their best RECIST response still had stable disease at week 3. In these cases tumor perfusion was already decreased and Ktrans heterogeneity showed no increase, indicating that the latter parameters seem to be more discriminative than RECIST at the 3-wk time point. CONCLUSION: PET and dynamic contrast-enhanced MRI were able to identify patients who benefit from bevacizumab and erlotinib treatment. Molecular imaging seems to allow earlier response evaluation than CT.
UNLABELLED: With antiangiogenic agents, tumor shrinkage may be absent, despite survival benefit. The present study assessed the predictive value of molecular imaging for the identification of survival benefit during antiangiogenic treatment with bevacizumab and erlotinib in patients with advanced non-small cell lung cancer. METHODS:Patients were evaluated using an imaging protocol including CT, 18F-FDG PET, H2(15)O PET, and dynamic contrast-enhanced MRI to derive measurements on tumor size, glucose metabolism, perfusion, and microvascular permeability. The percentage change in imaging parameters after 3 wk of treatment as compared with baseline was calculated and correlated with progression-free survival (PFS). RESULTS: Forty-four patients were included, and 40 underwent CT and 18F-FDG PET at both time points. Complete datasets, containing all imaging modalities, were available for 14 patients. Bevacizumab and erlotinib treatment resulted in decreased metabolism, perfusion, and tumor size. A decrease in standardized uptake value or tumor perfusion of more than 20% at week 3 was associated with longer PFS (9.7 vs. 2.8 mo, P=0.01, and 12.5 vs. 2.9 mo, P=0.009, respectively). Whole-tumor Ktrans (the endothelial transfer constant) was not associated with PFS, but patients with an increase of more than 15% in the SD of tumor Ktrans values-that is, an increase in regions with low or high Ktrans values-after 3 wk had shorter PFS (2.3 vs. 7.0 mo, P=0.008). A partial response, according to the response evaluation criteria in solid tumors (RECIST), at week 3 was also associated with prolonged PFS (4.6 vs. 2.9 mo, P=0.017). However, 40% of patients with a partial response as their best RECIST response still had stable disease at week 3. In these cases tumor perfusion was already decreased and Ktrans heterogeneity showed no increase, indicating that the latter parameters seem to be more discriminative than RECIST at the 3-wk time point. CONCLUSION: PET and dynamic contrast-enhanced MRI were able to identify patients who benefit from bevacizumab and erlotinib treatment. Molecular imaging seems to allow earlier response evaluation than CT.
Authors: Thomas Henzler; Jingyun Shi; Hashim Jafarov; Stefan O Schoenberg; Christian Manegold; Christian Fink; Gerald Schmid-Bindert Journal: Transl Lung Cancer Res Date: 2012-03
Authors: G Schmid-Bindert; Thomas Henzler; T Q Chu; M Meyer; J W Nance; U J Schoepf; D J Dinter; P Apfaltrer; R Krissak; C Manegold; S O Schoenberg; C Fink Journal: Eur Radiol Date: 2011-08-07 Impact factor: 5.315
Authors: L Heijmen; C J A Punt; E G W Ter Voert; L F de Geus-Oei; A Heerschap; J Bussink; C G J Sweep; V Zerbi; W J G Oyen; P N Span; O Boerman; H W M van Laarhoven Journal: Invest New Drugs Date: 2013-01-17 Impact factor: 3.850
Authors: P Veit-Haibach; D De Ruysscher; W van Elmpt; M Das; Martin Hüllner; H Sharifi; K Zegers; B Reymen; P Lambin; J E Wildberger; E G C Troost Journal: Radiother Oncol Date: 2013-09-14 Impact factor: 6.280
Authors: William N William; Apar Pataer; Neda Kalhor; Arlene M Correa; David C Rice; Ignacio I Wistuba; John Heymach; J Jack Lee; Edward S Kim; Reginald Munden; Kathryn A Gold; Vassiliki Papadimitrakopoulou; Stephen G Swisher; Jeremy J Erasmus Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609